Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211801 | 0.87 | PRKCA (0.45) | PRKCAELANETSHR | |
| SCHEMBL18651090 | 0.85 | PRKCA (0.39) | PRKCA | |
| SCHEMBL29278965 | 0.83 | ALDH1A1 (0.33) | PRKCATSHR | |
| SCHEMBL20561810 | 0.83 | — | — | |
| SCHEMBL10625022 | 0.82 | PRKCA (0.42) | PRKCAELANETSHR | |
| SCHEMBL15422936 | 0.78 | PRKCA (0.39) | PRKCAELANE | |
| SCHEMBL7606470 | 0.78 | TSHR (0.46) | PRKCAELANETSHR | |
| SCHEMBL5986707 | 0.78 | TSHR (0.46) | PRKCAELANETSHR | |
| SCHEMBL5986991 | 0.78 | TSHR (0.46) | PRKCAELANETSHR | |
| SCHEMBL13303725 | 0.78 | PRKCA (0.39) | PRKCAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946144-B2 | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1092720-B1 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | PRKCA 3458/4885ELANE 829/4885TSHR 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.